Top Pharma News - IgeaHub

Top Pharma News | February – March 2017

Amgen Announces the Efficay of Repatha® (Evolocumab) for Reducing the Risk of Cardiovascular Events February 2, 2017 Amgen has announced that the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial evaluating whether Repatha® (evolocumab) minimizes the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, … Continue reading Top Pharma News | February – March 2017

Advertisements
World's Most Admired Pharmaceutical Companies 2017

World’s Most Admired Pharmaceutical Companies 2017

Reputation is extremely important for Pharmaceutical Companies. Like every year, Fortune collaborated with Korn Ferry Hay Group on the survey of corporate reputations. To determine the best-regarded companies in 51 industries, Korn Ferry Hay Group evaluated 680 companies in 28 countries. Executives, directors, and analysts have been asked to rate enterprises in their own industry, here … Continue reading World’s Most Admired Pharmaceutical Companies 2017

Amgen Logo

Amgen Announces the Efficacy of Repatha® (Evolocumab) for Reducing The Risk Of Cardiovascular Events

Feb. 2, 2017 Amgen has announced that the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial evaluating whether Repatha® (evolocumab) minimizes the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal stroke, non-fatal myocardial infarction (MI), coronary revascularization or hospitalization for unstable angina) and … Continue reading Amgen Announces the Efficacy of Repatha® (Evolocumab) for Reducing The Risk Of Cardiovascular Events

Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies

Jan. 9, 2017 Amgen and Immatics Biotechnologies, a leading company in the field of cancer immunotherapy, have announced a research collaboration and exclusive license agreement for developing next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers. The collaboration will combine Amgen's validated Bispecific T-cell Engager (BiTE®) technology with Immatics' world-leading XPRESIDENT® target discovery and T-cell receptor (TCR) capabilities with the goal … Continue reading Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma 2016: One Year in Review

Lots of new things happened in the pharmaceutical industry in 2016. At igeahub.com, our mission is to make the pharmaceutical world simple and clear to everyone. We want our readers to have a privileged view on the key player in the healthcare system, and we do our best to keep things simple but highly accurate. The … Continue reading Pharma 2016: One Year in Review

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – November 2016

New Research Details Published by Merck Scientists About the Early Development of Verubecestat November 2, 2016 Merck has announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat. It is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is used … Continue reading Top Pharma News – November 2016

Top 15 biotech companies 2016 - Igeahub.com - Luca Dezzani

World’s Top 15 Biotech Companies 2016

The global biotechnology market was estimated to be USD 330.3 billion in 2015. The market is growing and the top-15 biotechnology players account for a market share of ~33% in 2015. These organizations are primarily located in U.S. and Europe. A comparative analysis of the top 15 biotechnology players was devised to develop a ranking … Continue reading World’s Top 15 Biotech Companies 2016

Biosimilars

Biosimilar Products and Its Commercial Potential

The increasing demand for medicines and other biologic products paved the way to the development of methods that can speed up its production in order to meet the needs of its consumers. One of which is the utilization of biosimilar product, which is defined by the U.S. Food and Drug Administration (FDA) as ‘a biological … Continue reading Biosimilar Products and Its Commercial Potential

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma Oncology | Top News – Fall 2016

AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen July 25, 2016 AbbVie and Bristol-Myers Squibb Company have announced a clinical trial collaboration for evaluating the safety, efficacy, and tolerability of investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) of AbbVie in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen … Continue reading Pharma Oncology | Top News – Fall 2016

Amgen Logo

Expanded Use Of ENBREL® (etanercept) is Approved by FDA for Treating Children with Chronic Moderate-To-Severe Plaque Psoriasis

Nov. 4, 2016 Amgen has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of ENBREL® (etanercept). This makes it the first and only systemic therapy for treating pediatric patients of ages 4 to 17 with chronic moderate-to-severe plaque psoriasis. Randy Beranek, president and chief executive officer … Continue reading Expanded Use Of ENBREL® (etanercept) is Approved by FDA for Treating Children with Chronic Moderate-To-Severe Plaque Psoriasis